English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsTorrentpharmaceuticals

    Jump to
    • Will continue to pursue inorganic growth in India & US: Torrent Pharma

      Will continue to pursue inorganic growth in India & US: Torrent Pharma

      In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

    • M&A in 2017: Best in a decade

      M&A in 2017: Best in a decade

      The Torrent Pharmaceuticals and Unichem Laboratories deal is close to fruition. On a day this Rs 3600 crore deal has been sealed, it is a good time to look at M&A activity in 2017 so far. In an interview to CNBC-TV18, Raja Lahiri of Grant Thornton, Randhir Kochhar of Ernst & Young, Vivek Gupta of KPMG and Ashvin Parekh of Ashvin Parekh Advisory Services discussed about the same.

    • Torrent to acquire Unichem's domestic branded business for Rs 3,600 crore

      Torrent to acquire Unichem's domestic branded business for Rs 3,600 crore

      Torrent will fund the acquisition through a mix of internal accruals and bank borrowings.

    • Eyeing inorganic opportunities to increase growth: Torrent

      Eyeing inorganic opportunities to increase growth: Torrent

      Samir Mehta of Torrent Pharma says integration with Elder Pharma has worked out well and will become cash-accretive by next year.

    • Expect Rs 600-700cr sales from overseas biz: Elder Pharma

      Expect Rs 600-700cr sales from overseas biz: Elder Pharma

      Elder Pharma recently sold one of its key brands, Shelcal, to Torrent Pharma. Post the sale, Elder is focusing on remaining brands, including Eldervit and Somazina.

    • Looking at a turnover of Rs 200cr from domestic biz: Elder

      Looking at a turnover of Rs 200cr from domestic biz: Elder

      In the long-term, Elder Pharma plans to bring products from the R&D pipeline, actively being worked on in the UK, and launch them in the Indian market, says Alok Saxena, Joint MD, Elder Pharma.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347